Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia - Examination of practice in Germany

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2751-2756

  Steinmetz, T ^a,e   Totzke, U ^b   Soling U ^c   Groschek, M ^d   Mittermuller J ^d   Schweigert, M ^d   Tesch, H ^d   Nawka, S ^d   Schmitz, S ^a   Tsamaloukas, A ^d  

^a Outpatient Clinic for Oncology and Haematology   (Germany)

^b Hlthcare and Project Management HPM   (Switzerland)

^c Oncological Outpatient Clinics   (Germany)

^d NONE

^e Gemeinschaftspraxis für Hämatologie und Onkologie Köln   (Germany)

Author keywords

Cancer associated anemia; Erythropoiesis stimulating agent; Hemoglobin; In use study; Registry

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE REGISTRY; DRUG FATALITY; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; GERMANY; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; SOLID TUMOR; THROMBOEMBOLISM; VOMITING;

EID: 55549128250     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802377057     Document Type: Article

References (23)

1. Glaspy J, Smith R, Aapro M, et al. Results from a Phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. AACR Annual Meeting; 2007; Los Angeles, CA; 2007.
2. Goldberg P. Danish researchers post long-awaited Aranesp results - ever so discretely. Cancer Lett 2007;33:1
3. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-6
4. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72
5. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 20071; 25:1027-32
6. Oncologic Drugs Advisory Committee Meeting. http://wwwfdagov/ohrms/ dockets/ac/07/slides/2007-4301s2-00-indexhtm 2007 [cited 2007 December 08]
7. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane database of systematic reviews (Online) 2006;3:CD003407
8. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-14
9. Erythropoetin: Ergebnisse klinischer Studien an onkologischen Patienten mit oder ohne Anämie. http://wwwbfarmde/nn_424276/DE/ Pharmakovigilanz/risikoinfo/erythropoetinhtml_nnn=true 2007 16.8.2007 [cited 2007 December, 8]; Available from: http://www.bfarm.de/nn_424276/ DE/Pharmakovigilanz/risikoinfo/erythropoetin.html_nnn=true
10. European Medicines Agency starts review of the safety of epoetins. http://wwwemeaeuropaeu/pdfs/human/press/pus/18806807enpdf 2007 16.08.2007 [cited 2008 December, 8]; Available from: http://www.emea.europa.eu/pdfs/ human/press/pus/18806807en.pdf
11. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-76
12. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
13. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007;356:2445-8
14. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 2007;12:362-5
15. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20: 4083-107
16. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20
17. Steinmetz T, Hellmich M, Neise M, et al. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. The oncologist 2007;12:748-55
18. Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 2002;29:45-54
19. Barrett-Lee P, Bokemeyer C, Gascon P, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10: 743-57
20. Birgegard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 2006 Nov;77(5):378-86
21. Engelhardt M, Thierry V, Aulitzky W. Behandlung mit hämatopoetischen Wachstumsfaktoren (HGF). http://wwwdghode/_cmsdata/_file/file_137pdf
22. Bundesärztekammer WBd. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutsches Ärzteblatt. 2002 6. December 2002;99(49)
23. Hess G, Hill J, Clough J, et al. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels. Curr Med Res Opin 2008;24:815-19